Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies

IMPORTANCE: Phase 1 cancer studies, which guide dose selection for subsequent studies, are almost 3 times more prevalent than phase 3 studies and have a median study duration considerably longer than 2 years, which constitutes a major component of drug development time. OBJECTIVE: To discern a metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankel, Paul H., Chung, Vincent, Tuscano, Joseph, Siddiqi, Tanya, Sampath, Sagus, Longmate, Jeffrey, Groshen, Susan, Newman, Edward M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221509/
https://www.ncbi.nlm.nih.gov/pubmed/32401317
http://dx.doi.org/10.1001/jamanetworkopen.2020.4787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221509/
https://www.ncbi.nlm.nih.gov/pubmed/32401317
http://dx.doi.org/10.1001/jamanetworkopen.2020.4787

Ejemplares similares